LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
Armin Bender(Georg Speyer Haus), Elke Jäger(Krankenhaus Nordwest), Antje Neumann(Krankenhaus Nordwest), Melina Biskamp, Sacha Gnjatic(Tisch Hospital), Lloyd J. Old(Gynecologic Oncology Group), Julia Karbach(Memorial Sloan Kettering Cancer Center), Alexander Knuth(National Center for Cancer Care and Research), Eckhart Weidmann(Krankenhaus Nordwest), Linda Pan(Memorial Sloan Kettering Cancer Center), S. Al-Batran(Krankenhaus Nordwest), Eric W. Hoffman(Cornell University), Dirk Jäger(Memorial Sloan Kettering Cancer Center), Akin Atmaca(Heidelberg University)
PubMed
October 19, 2007
Cited by 53
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k